T. Rowe Price Associates
CYCN icon

T. Rowe Price Associates’s Cyclerion Therapeutics CYCN Stock Holding History

T. Rowe Price Associates’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-35,815
Closed -$4.36M – 2678
2020
Q3 		$4.36M Buy
35,815
+4,839
+16% +$553K ﹤0.01% 1419
2020
Q2 		$3.66M Sell
30,976
-2,958
-9% -$247K ﹤0.01% 1421
2020
Q1 		$1.8M Buy
+33,934
New +$2.42M ﹤0.01% 1527
2019
Q4 		– Sell
-11,598
Closed -$2.81M – 2534
2019
Q3 		$2.81M Buy
11,598
+4,010
+53% +$866K ﹤0.01% 1489
2019
Q2 		$1.74M Buy
+7,588
New +$2.15M ﹤0.01% 1635

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates's CYCN Position: Q4 2020 in Review

T. Rowe Price Associates sold out of Cyclerion Therapeutics (CYCN) in Q4 2020, closing a stake of 35,815 shares — an estimated $4.36M sold.

T. Rowe Price Associates first reported a position in CYCN in Q2 2019 and held it in 5 quarters. The position peaked at $4.36M in Q3 2020. 73 funds tracked by Wall St. Rank hold CYCN as of Q4 2020.

  • T. Rowe Price Associates reported no remaining Cyclerion Therapeutics position as of Q4 2020 after selling out during the quarter.
  • T. Rowe Price Associates sold 35,815 Cyclerion Therapeutics shares in Q4 2020, an estimated $4.36M.
  • T. Rowe Price Associates first reported a position in Cyclerion Therapeutics in Q2 2019 and held it in 5 quarters.
  • T. Rowe Price Associates's Cyclerion Therapeutics position peaked at $4.36M in Q3 2020.
  • 73 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q4 2020.

Based on T. Rowe Price Associates's 13F filing for Q4 2020, filed 16 Feb 2021.